PAD Inhibitors as a Potential Treatment for SARS-CoV-2 Immunothrombosis

Since the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, the virus’s dynamicity has resulted in the evolution of various variants, including the delta variant and the more novel mu variant. With a multitude of mutant strains posing as challenges to vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Elliott, Willie, Guda, Maheedhara R., Asuthkar, Swapna, Teluguakula, Narasaraju, Prasad, Durbaka V. R., Tsung, Andrew J., Velpula, Kiran K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698348/
https://www.ncbi.nlm.nih.gov/pubmed/34944683
http://dx.doi.org/10.3390/biomedicines9121867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698348/
https://www.ncbi.nlm.nih.gov/pubmed/34944683
http://dx.doi.org/10.3390/biomedicines9121867

Ejemplares similares